ALLIANCES AND COLLABORATIONS (AstraZeneca) (Details) (USD $)	3 Months Ended		6 Months Ended			3 Months Ended		6 Months Ended		3 Months Ended	6 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended				6 Months Ended					3 Months Ended	6 Months Ended		3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Jun. 30, 2013 Onglyza Kombiglyze [Member]	Jun. 30, 2012 Onglyza Kombiglyze [Member]	Jun. 30, 2013 Onglyza Kombiglyze [Member]	Jun. 30, 2012 Onglyza Kombiglyze [Member]	Jun. 30, 2013 Forxiga [Member]	Jun. 30, 2013 Forxiga [Member]	Jun. 30, 2013 AstraZeneca [Member]	Jun. 30, 2012 AstraZeneca [Member]	Jun. 30, 2013 AstraZeneca [Member]	Jun. 30, 2012 AstraZeneca [Member]	Dec. 31, 2012 AstraZeneca [Member] Amylin Acquisition [Member]	Jun. 30, 2013 AstraZeneca [Member] Amylin Acquisition [Member]	Jun. 30, 2013 AstraZeneca [Member] Onglyza Kombiglyze [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2012 AstraZeneca [Member] Onglyza Kombiglyze [Member] Upfront, milestone and other licensing payments [Member]	Jun. 30, 2013 AstraZeneca [Member] Forxiga [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2012 AstraZeneca [Member] Forxiga [Member] Upfront, milestone and other licensing payments [Member]	Jun. 30, 2012 AstraZeneca [Member] Forxiga [Member] Upfront, milestone and other licensing payments [Member]	Jun. 30, 2013 AstraZeneca [Member] Amylin Related Products [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2012 AstraZeneca [Member] Amylin Related Products [Member] Upfront, milestone and other licensing payments [Member]	Jun. 30, 2013 AstraZeneca [Member] Amylin Related Products [Member] Amortization Income Expense [Member]	Jun. 30, 2013 AstraZeneca [Member] Amylin Related Products [Member] Amortization Income Expense [Member]	Jun. 30, 2013 AstraZeneca [Member] Amylin Related Products [Member] Amylin Acquisition [Member]	Jun. 30, 2013 AstraZeneca [Member] Onglyza, Kombiglyze and Forxiga [Member] Amortization Income Expense [Member]	Jun. 30, 2012 AstraZeneca [Member] Onglyza, Kombiglyze and Forxiga [Member] Amortization Income Expense [Member]	Jun. 30, 2013 AstraZeneca [Member] Onglyza, Kombiglyze and Forxiga [Member] Amortization Income Expense [Member]	Jun. 30, 2012 AstraZeneca [Member] Onglyza, Kombiglyze and Forxiga [Member] Amortization Income Expense [Member]	Jun. 30, 2013 AstraZeneca [Member] Onglyza Kombiglyze Forxiga And Amylin Related Products [Member]	Jun. 30, 2012 AstraZeneca [Member] Onglyza Kombiglyze Forxiga And Amylin Related Products [Member]	Jun. 30, 2013 AstraZeneca [Member] Onglyza Kombiglyze Forxiga And Amylin Related Products [Member]	Jun. 30, 2012 AstraZeneca [Member] Onglyza Kombiglyze Forxiga And Amylin Related Products [Member]
Alliances and Collaborations Statement [Line Items]
Number of agreements in collaboration												3		3
Payment made by a collaboration partner to enter into a collaboration agreement																$ 3,600,000,000
Portion of preliminary proceeds included in accrued expenses related to collaboration proceeds adjustments																	73,000,000
Weighted average useful life - property, plant and equipment																											15 years 0 months 0 days
Weighted average useful life - acquired intangible assets																											12 years 0 months 0 days
Payment to be made by a collaboration partner to establish equal governance rights in the collaboration																	135,000,000
The percentage of capital expenditures to be reimbursed by AstraZeneca																	50.00%
Payment made by collaboration partner as part of tax sharing agreement																207,000,000
Total upfront, milestone and other licensing payments received																		300,000,000				250,000,000
Potential additional development and regulatory milestone receipts																				150,000,000
Potential additional sales based milestone receipts																		300,000,000		390,000,000
Net Sales	4,048,000,000	4,443,000,000	7,879,000,000	9,694,000,000		240,000,000	172,000,000	442,000,000	333,000,000	5,000,000	8,000,000																					431,000,000	172,000,000	789,000,000	333,000,000
Profit sharing expense												178,000,000	77,000,000	324,000,000	150,000,000
Commercialization expense reimbursements to/(from) alliance partner												(82,000,000)	(7,000,000)	(139,000,000)	(19,000,000)
Research and development reimbursements to/(from) collaboration partner												(22,000,000)	6,000,000	(39,000,000)	10,000,000
Other (income)/expense	199,000,000	(51,000,000)	180,000,000	(235,000,000)																								(8,000,000)	(11,000,000)	(15,000,000)	(21,000,000)
Cost of products sold	1,108,000,000	1,245,000,000	2,171,000,000	2,548,000,000																					(74,000,000)	(149,000,000)
Upfront, milestone and other licensing payments received																				80,000,000
Deferred income	$ 5,132,000,000		$ 5,132,000,000		$ 4,849,000,000											$ 3,500,000,000		$ 200,000,000	$ 208,000,000	$ 199,000,000	$ 206,000,000		$ 3,279,000,000	$ 3,423,000,000